Annals of Emergency Medicine
Volume 45, Issue 4 , Pages 355-362, April 2005

Influence of Timing of Troponin Elevation on Clinical Outcomes and Use of Evidence-Based Therapies for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

From the Duke Clinical Research Institute, Durham, NC (Roe, Peterson, Newby, Li); Pennsylvania Hospital, Philadelphia, PA (Pollack); University of Maryland School of Medicine, Baltimore, MD (Christenson); Cleveland Clinic Foundation, Cleveland, OH (Peacock); Erlanger Medical Center, Chattanooga, TN (Fesmire); University of California–Davis, Sacramento, CA (Diercks, Kirk); University of Cincinnati College of Medicine, Cincinnati, OH (Gibler); and University of North Carolina School of Medicine, Chapel Hill, NC (Smith, Ohman)

Received 18 August 2004; received in revised form 8 October 2004; accepted 12 October 2004. published online 07 February 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Author contributions: MTR, EDP, WBG, and EMO conceived the study, designed the study, and obtained research funding. MTR, EDP, and LKN supervised the conduct of the study and data collection. CVP, RHC, WFP, FMF, DD, JDK, and SCS provided input into the study design, interpretation of the data, and writing of the manuscript. YL provided statistical advice on study design and analyzed the data. MTR drafted the manuscript, and all authors contributed substantially to its revision. MTR takes responsibility for the paper as a whole.Funding and support: CRUSADE is funded by Millennium Pharmaceuticals, Inc., and Schering Corporation. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides an unrestricted grant in support of the program.Reprints not available from the authors.

PII: S0196-0644(04)01555-0

doi:10.1016/j.annemergmed.2004.10.016

Annals of Emergency Medicine
Volume 45, Issue 4 , Pages 355-362, April 2005

Article Tools